Expanded Access Protocol Using HBOC-201
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- 试验地点
- 1
研究概览
简要总结
The purpose of this protocol is to provide treatment with HBOC-201 to patients with life-threatening anemia for whom blood is not an option. Such patients may also be referred to in this document as patients who refuse blood transfusion (PWRBT). Other patients who potentially may require HBOC-201 treatment include those with red blood cell alloantibodies for whom immunologically compatible red blood cell units cannot be found, although these patients are less common than PWRBT.
详细描述
This is an open label intermediate-size patient population expanded access IND protocol.
Due to our experience with management of severely anemic patients for whom blood is not an option, we anticipate encountering future patients with life-threatening anemia for whom blood is not an option. Blood is not an option in the following circumstances:
- refusal of transfusion
- lack of compatible red blood cells due to alloimmunity
All patients with life-threatening anemia for whom blood is not an option will be treated as per the standard procedure. If those measures are not successful and the life-threatening anemia persists, then at the investigator's discretion treatment with HBOC-201 will then be considered.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥ 18 years of age
- •Critically ill patients with hemoglobin < 5 g/dL (or 6-7 g/dL with significant active bleeding), and physiologic evidence of critical ischemia, for example: elevated troponins, altered mental status, acute renal failure, lactic acidosis or evidence of central nervous system acute deficits
- •Patients or their Legally Authorized Representative who are able and willing to provide informed consent
- •Blood is not an option due to:
- •refusal of transfusion
- •lack of compatible red blood cells
排除标准
- •Patients with known hypersensitivity or allergy to beef products
- •Patients with pre-existing uncontrolled hypertension, heart failure, renal failure, circulatory hypervolemia or systemic mastocytosis*
- •Patients who are eligible for blood transfusions
- •Patients who are > 80 years old*
- •on a case by case and quality of life determination
研究者
Mauricio Lynn
Professor of Surgery
University of Miami